

Pharmacokinetic Interactions with Rifampicin

Clinical Pharmacokinetics

42, 819-850

DOI: 10.2165/00003088-200342090-00003

Citation Report

#	ARTICLE	IF	CITATIONS
1	Degradation of Myxovirus Virion RNA by Periodate. <i>Intervirology</i> , 1975, 5, 150-161.	1.2	3
2	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 427-432.	1.1	40
3	Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 181-187.	1.1	66
5	CYP3A induction aggravates endotoxemic liver injury via reactive oxygen species in male rats. <i>Free Radical Biology and Medicine</i> , 2004, 37, 703-712.	1.3	35
6	An in vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and quantitative RT-PCR. <i>Chemico-Biological Interactions</i> , 2004, 151, 1-11.	1.7	56
7	Rifampicin reduces plasma concentrations of celiprolol. <i>European Journal of Clinical Pharmacology</i> , 2004, 59, 819-824.	0.8	19
8	Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 109-114.	0.8	71
10	Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 239-249.	2.3	80
11	Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 250-269.	2.3	213
12	Current use for old antibacterial agents: polymyxins, rifampin, and aminoglycosides. <i>Infectious Disease Clinics of North America</i> , 2004, 18, 669-689.	1.9	28
13	Methadone's metabolism, pharmacokinetics and interactions. <i>Pharmacological Research</i> , 2004, 50, 551-559.	3.1	318
14	Once-Daily Regimen of Saquinavir, Ritonavir, Didanosine, and Lamivudine in HIV-Infected Patients With Standard Tuberculosis Therapy (TBQD Study). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 317-323.	0.9	26
15	Drug interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphate-glucuronosyltransferase. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 81-88.	2.3	71
16	Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 154-167.	2.3	132
17	Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 199-206.	1.1	87
18	No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. <i>Hepatology</i> , 2005, 41, 595-602.	3.6	44
19	Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005, 77, 460-464.	2.5	21
22	Rifampin-Resistant RNA Polymerase Mutants of <i>Chlamydia trachomatis</i> Remain Susceptible to the Ansamycin Rifalazil. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1120-1126.	1.4	38

#	ARTICLE	IF	CITATIONS
23	IN VIVO INDUCTION OF HUMAN CYTOCHROME P450 ENZYMES EXPRESSED IN CHIMERIC MICE WITH HUMANIZED LIVER. <i>Drug Metabolism and Disposition</i> , 2005, 33, 754-763.	1.7	55
24	In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver. <i>Xenobiotica</i> , 2005, 35, 863-875.	0.5	39
25	Simultaneous Substitution of Phenylalanine-305 and Aspartate-318 of Rat Pregnane X Receptor with the Corresponding Human Residues Abolishes the Ability to Transactivate the CYP3A23 Promoter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 571-582.	1.3	18
26	Interactions of Anti-Infectives: A Review. <i>Chemotherapy</i> , 2005, 51, 197-199.	0.8	7
27	Drug-Drug Interactions and HIV Therapy: What Should Pharmacists Know?. <i>Journal of Pharmacy Practice</i> , 2005, 18, 278-294.	0.5	13
28	Interaction of Warfarin With Drugs, Natural Substances, and Foods. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 127-132.	1.0	162
29	Animal Models of Xenobiotic Receptors in Drug Metabolism and Diseases. <i>Methods in Enzymology</i> , 2005, 400, 598-618.	0.4	30
31	Drug Interactions of Clinical Importance with Antihyperglycaemic Agents. <i>Drug Safety</i> , 2005, 28, 601-631.	1.4	121
32	Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir. <i>Clinical Pharmacokinetics</i> , 2005, 44, 1035-1050.	1.6	139
33	Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 821-836.	1.0	19
34	Anti-inflammatory activity of ansamycins. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 91-103.	2.0	9
35	Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 961-979.	1.5	10
36	Contribution of CYP2C9 to variability in vitamin K antagonist metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 3-15.	1.5	13
37	Human Pregnane X Receptor: Genetic Polymorphisms, Alternative mRNA Splice Variants, and Cytochrome P450 3A Metabolic Activity. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1356-1369.	1.0	22
38	Antibiotic Drug Interactions. <i>Medical Clinics of North America</i> , 2006, 90, 1223-1255.	1.1	58
39	Tuberculosis and HIV Co-Infection. <i>Drugs</i> , 2006, 66, 2299-2308.	4.9	56
40	Drug-induced changes in P450 enzyme expression at the gene expression level: A new dimension to the analysis of drug-drug interactions. <i>Xenobiotica</i> , 2006, 36, 1013-1080.	0.5	28
41	Investigation of the Effects of Herbal Medicines on Warfarin Response in Healthy Subjects: A Population Pharmacokinetic-Pharmacodynamic Modeling Approach. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1370-1378.	1.0	78

#	ARTICLE	IF	CITATIONS
42	Relationship between Excretion Clearance of Rhodamine 123 and P-Glycoprotein (Pgp) Expression Induced by Representative Pgp Inducers. <i>Biological and Pharmaceutical Bulletin</i> , 2006, 29, 779-784.	0.6	63
43	Effect of Simultaneous Insertion of Oleaginous Base on the Absorption and on the Anticonvulsant Effect of Diazepam Suppository. <i>Biological and Pharmaceutical Bulletin</i> , 2006, 29, 705-708.	0.6	6
44	Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 565-568.	0.7	40
45	Rifampicin Markedly Decreases Plasma Concentration and Hypnotic Effect of Brotizolam. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 299-302.	1.0	5
46	Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2006, 5, 3.	1.7	206
47	Effect of Rifampicin on the Pharmacokinetics of Atenolol. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 555-558.	1.2	16
48	Effect of rifampicin on the pharmacokinetics of pioglitazone. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 70-78.	1.1	75
49	Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 200-210.	1.1	12
50	A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 138-147.	1.1	9
51	Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 72-89.	2.3	91
52	Effect of benzo[a]pyrene on P-glycoprotein-mediated transport in Caco-2 cell monolayer. <i>Toxicology</i> , 2006, 223, 156-165.	2.0	18
53	Impact of transporter-mediated drug absorption, distribution, elimination and drug interactions in antimicrobial chemotherapy. <i>Journal of Infection and Chemotherapy</i> , 2006, 12, 241-250.	0.8	33
54	Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 451-461.	0.8	59
55	Update on the Interaction of Rifampin and Warfarin. <i>Progress in Cardiovascular Nursing</i> , 2006, 21, 1-4.	0.5	2
56	Expression and function of efflux drug transporters in the intestine. , 2006, 109, 137-161.		311
57	Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, 112, 71-105.		501
58	A reporter gene cellular model for evaluating induction of CYP3A4 by new chemical entities. <i>Drug Development Research</i> , 2006, 67, 470-475.	1.4	4
59	Rifampin Induces the in Vitro Oxidative Metabolism, but Not the in Vivo Clearance of Diclofenac in Rhesus Monkeys. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1806-1810.	1.7	8

#	ARTICLE	IF	CITATIONS
60	In Vitro and in Vivo CYP3A64 Induction and Inhibition Studies in Rhesus Monkeys: A Preclinical Approach for CYP3A-Mediated Drug Interaction Studies. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1546-1555.	1.7	31
61	Individualizing analgesic prescription Part I: pharmacogenetics of opioid analgesics. <i>Personalized Medicine</i> , 2006, 3, 239-269.	0.8	10
62	Efficacy of Novel Rifamycin Derivatives against Rifamycin-Sensitive and -Resistant <i>Staphylococcus aureus</i> Isolates in Murine Models of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3658-3664.	1.4	17
63	An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 935-952.	2.5	939
64	Efficacy of a Novel Rifamycin Derivative, ABI-0043, against <i>Staphylococcus aureus</i> in an Experimental Model of Foreign-Body Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2540-2545.	1.4	45
65	Development of <i>In Vitro</i> Methods to Predict Induction of CYP1A2 and CYP3A4 in Humans. <i>Assay and Drug Development Technologies</i> , 2007, 5, 793-804.	0.6	6
66	The Pregnane X Receptor Gene-Humanized Mouse: A Model for Investigating Drug-Drug Interactions Mediated by Cytochromes P450 3A. <i>Drug Metabolism and Disposition</i> , 2007, 35, 194-200.	1.7	131
67	The Dietary Isothiocyanate Sulforaphane Is an Antagonist of the Human Steroid and Xenobiotic Nuclear Receptor. <i>Molecular Pharmacology</i> , 2007, 71, 220-229.	1.0	171
68	Absence of Effect of Oral Rifaximin on the Pharmacokinetics of Ethinyl Estradiol/Norgestimate in Healthy Females. <i>Annals of Pharmacotherapy</i> , 2007, 41, 222-228.	0.9	35
69	Deep venous thrombosis associated with tuberculosis. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 377-380.	0.5	30
70	Dual Effects of Rifampin on the Pharmacokinetics of Atrasentan. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 423-429.	1.0	24
71	Effects of benzo(e)pyrene and benzo(a)pyrene on P-glycoprotein-mediated transport in Caco-2 cell monolayer: A comparative approach. <i>Toxicology in Vitro</i> , 2007, 21, 827-834.	1.1	16
72	The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. <i>Cancer Treatment Reviews</i> , 2007, 33, 369-380.	3.4	111
74	Application of Chimeric Mice with Humanized Liver for Predictive ADME. <i>Drug Metabolism Reviews</i> , 2007, 39, 145-157.	1.5	51
75	Pharmacokinetic Drug Interactions Involving 17 β -Ethinylestradiol. <i>Clinical Pharmacokinetics</i> , 2007, 46, 133-157.	1.6	147
76	The role of cytochrome P450 in antiretroviral drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 583-598.	1.5	71
77	Pharmacokinetic Profile of Temeirolimus With Concomitant Administration of Cytochrome P450 ¹ -Inducing Medications. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 1430-1439.	1.0	46
78	Pay attention to drug interactions to ensure successful treatment of tuberculosis and HIV co-infection. <i>Drugs and Therapy Perspectives</i> , 2007, 23, 16-17.	0.3	0

#	ARTICLE	IF	CITATIONS
79	Pharmacokinetic Interactions with Thiazolidinediones. <i>Clinical Pharmacokinetics</i> , 2007, 46, 1-12.	1.6	53
80	Drug-Drug and Food-Drug Pharmacokinetic Interactions with New Insulinotropic Agents Repaglinide and Nateglinide. <i>Clinical Pharmacokinetics</i> , 2007, 46, 93-108.	1.6	64
81	Successful Treatment of Propafenone, Digoxin and Warfarin Overdosage with Plasma Exchange Therapy and Rifampicin. <i>Clinical Drug Investigation</i> , 2007, 27, 505-508.	1.1	19
82	Role of OATP transporters in the disposition of drugs. <i>Pharmacogenomics</i> , 2007, 8, 787-802.	0.6	241
83	Modeling and Simulation of Pharmacokinetic Aspects of Cytochrome P450-Based Metabolic Drug-Drug Interactions. , 2007, , 827-846.		2
84	Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: Drug metabolism and its related interactions. <i>World Journal of Gastroenterology</i> , 2007, 13, 5618.	1.4	11
86	Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 194-204.	2.3	297
87	Inhibitory and Inductive Effects of Rifampin on the Pharmacokinetics of Bosentan in Healthy Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 414-419.	2.3	76
88	Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 726-733.	2.3	381
89	<i>OATP1B1</i> POLYMORPHISM IS A MAJOR DETERMINANT OF SERUM BILIRUBIN LEVEL BUT NOT ASSOCIATED WITH RIFAMPICIN-MEDIATED BILIRUBIN ELEVATION. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007, 34, 1240-1244.	0.9	72
90	Decreased Serum Linezolid Levels in a Critically Ill Patient Receiving Concomitant Linezolid and Rifampin. <i>Pharmacotherapy</i> , 2007, 27, 476-479.	1.2	76
91	Clozapine-rifampicin interaction in a patient with pulmonary tuberculosis. <i>General Hospital Psychiatry</i> , 2007, 29, 281-282.	1.2	16
92	Update on the Interaction of Rifampin and Warfarin. <i>Progress in Cardiovascular Nursing</i> , 2007, 22, 97-100.	0.5	20
93	Inhibition and induction of human cytochrome P450 enzymes: current status. <i>Archives of Toxicology</i> , 2008, 82, 667-715.	1.9	481
94	In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 378, 275-282.	1.4	17
95	Development and evaluation of an in vivo assay in <i>Caenorhabditis elegans</i> for screening of compounds for their effect on cytochrome P450 expression. <i>Journal of Biosciences</i> , 2008, 33, 269-277.	0.5	24
96	Chimeric mice with humanized liver. <i>Toxicology</i> , 2008, 246, 9-17.	2.0	83
97	Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4 β -Hydroxycholesterol. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 589-594.	2.3	120

#	ARTICLE	IF	CITATIONS
98	The influence of polymorphisms of <i>VKORC1</i> and <i>CYP2C9</i> on major gastrointestinal bleeding risk in anticoagulated patients. <i>British Journal of Haematology</i> , 2008, 143, 727-733.	1.2	11
99	The recovery time-course of CYP3A after induction by St John's wort administration. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 701-707.	1.1	50
100	Concomitant Use of Voriconazole and Rifabutin in a Patient with Multiple Infections. <i>Pharmacotherapy</i> , 2008, 28, 1076-1080.	1.2	22
101	Clinical Relevance of Pharmacokinetics and Pharmacodynamics in Cardiac Critical Care Patients. <i>Clinical Pharmacokinetics</i> , 2008, 47, 449-462.	1.6	30
102	General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information. <i>Clinical Pharmacokinetics</i> , 2008, 47, 669-680.	1.6	96
103	Lipid Microsphere Formulation Containing Rifampicin Targets Alveolar Macrophages. <i>Drug Delivery</i> , 2008, 15, 169-175.	2.5	22
104	Dear Dr. Walson. <i>Clinical Therapeutics</i> , 2008, 30, 1932-1933.	1.1	2
105	Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: A randomized, single-blind, placebo-controlled, crossover study. <i>Clinical Therapeutics</i> , 2008, 30, 1283-1289.	1.1	29
106	Pregnane X Receptor: Prediction and Attenuation of Human CYP3A4 Enzyme Induction and Drug-Drug Interactions. <i>Annual Reports in Medicinal Chemistry</i> , 2008, 43, 405-418.	0.5	10
107	Interindividual Variability of Methadone Response. <i>Molecular Diagnosis and Therapy</i> , 2008, 12, 109-124.	1.6	126
108	A Survey of the Use of Herbs Among Patients Attending Secondary-Level Health Care Facilities in Southwestern Nigeria. <i>Journal of Herbal Pharmacotherapy: Innovations in Clinical and Applied Evidence-based Herbal Medicinals</i> , 2008, 7, 213-227.	0.1	21
109	Different Effects of <i>SLCO1B1</i> Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 311-321.	1.0	83
110	Rifampicin induces MDR1 expression in <i>Candida albicans</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 541-547.	1.3	22
111	A Double Transgenic Mouse Model Expressing Human Pregnane X Receptor and Cytochrome P450 3A4. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2506-2512.	1.7	56
112	Substrate-Dependent Effects of Human <i>ABCB1</i> Coding Polymorphisms. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 325, 435-442.	1.3	49
113	Pharmacogenetics of analgesics: toward the individualization of prescription. <i>Pharmacogenomics</i> , 2008, 9, 905-933.	0.6	91
114	Drug Interactions Involving Combination Antiretroviral Therapy and Other Anti-Infective Agents: Repercussions for Resource-Limited Countries. <i>Journal of Infectious Diseases</i> , 2008, 198, 948-961.	1.9	78
115	The pregnane X receptor: from bench to bedside. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 895-908.	1.5	113

#	ARTICLE	IF	CITATIONS
116	Nuclear Receptor-Mediated Regulation of Drug Transporters. , 0, , 111-146.		0
117	Design of antiretroviral drug interaction studies. Current Opinion in HIV and AIDS, 2008, 3, 313-318.	1.5	1
118	Global HIV and Dermatology. , 2008, , 237-250.		0
119	Coccidioidomycosis and Tuberculosis Coinfection at a Tuberculosis Hospital. Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlock 10 0.4 19		19
120	The utility of nucleos(t)ide-only regimens in the treatment of Mycobacterium tuberculosisâ€“HIV-1 coinfection. Aids, 2009, 23, 865-867.	1.0	2
121	Antifungal Azole Metabolites: Significance in Pharmaceutical and Biomedical Analysis. Journal of Medical Biochemistry, 2009, 28, 1-10.	0.7	3
122	The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: An open-label, one-sequence, three-period, three-treatment crossover study. Clinical Therapeutics, 2009, 31, 3009-3020.	1.1	16
123	Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Medicine, 2009, 35, 603-612.	3.9	62
124	4Î²â€“Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and halfâ€“life of elimination after induction with rifampicin. British Journal of Clinical Pharmacology, 2009, 67, 38-43.	1.1	105
125	<i>CYP2B6</i> (c.516Gâ†T) and <i>CYP2A6</i> (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIVâ€“infected patients. British Journal of Clinical Pharmacology, 2009, 67, 427-436.	1.1	110
126	Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast Nâ€“oxide in healthy subjects. British Journal of Clinical Pharmacology, 2009, 68, 580-587.	1.1	42
127	Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite. Clinical Pharmacology and Therapeutics, 2009. 85, 78-85.	2.3	119
128	Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2009, 86, 54-61.	2.3	44
129	Impact of OATP transporters on pharmacokinetics. British Journal of Pharmacology, 2009, 158, 693-705.	2.7	783
130	Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1771-1777.	1.2	51
131	New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrobial Agents and Chemotherapy, 2009, 53, 849-862.	1.4	213
132	Long-lasting enhancement of CYP activity after discontinuation of repeated administration of phenobarbital in dogs. Research in Veterinary Science, 2009, 87, 455-457.	0.9	8
133	Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Molecular Aspects of Medicine, 2009, 30, 297-343.	2.7	246

#	ARTICLE	IF	CITATIONS
134	Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies. <i>Drug Safety</i> , 2009, 32, 1017-1039.	1.4	19
135	Toward an Optimized Therapy for Tuberculosis? Drugs in Clinical Trials and in Preclinical Development. <i>Clinics in Chest Medicine</i> , 2009, 30, 755-768.	0.8	21
136	Immunotherapy in Elderly Transplant Recipients. <i>Drugs and Aging</i> , 2009, 26, 715-737.	1.3	68
137	Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. <i>Current Medical Research and Opinion</i> , 2009, 25, 1821-1829.	0.9	31
138	Tuberculosis and diabetes mellitus: convergence of two epidemics. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 737-746.	4.6	715
139	Effectiveness and Safety of Antiretrovirals with Rifampicin: Crucial Issues for High-Burden Countries. <i>Antiviral Therapy</i> , 2009, 14, 1039-1043.	0.6	47
140	Propofol Reduces the Distribution and Clearance of Midazolam. <i>Anesthesia and Analgesia</i> , 2010, 110, 1597-1606.	1.1	33
141	Management of individuals requiring antiretroviral therapy and TB treatment. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 61-69.	1.5	67
142	Cytochrome P450-mediated metabolism in the human gut wall. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 541-558.	1.2	213
143	Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 563-570.	1.1	68
144	Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 497-502.	0.8	24
145	Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 865-870.	0.8	7
146	Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1017-1023.	0.8	23
147	Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. , 2010, 125, 230-248.		87
148	Rifamycins – Obstacles and opportunities. <i>Tuberculosis</i> , 2010, 90, 94-118.	0.8	155
149	Implications of the global increase of diabetes for tuberculosis control and patient care. <i>Tropical Medicine and International Health</i> , 2010, 15, 1289-1299.	1.0	179
150	Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. <i>Journal of Internal Medicine</i> , 2010, 268, 530-539.	2.7	61
151	Effect of Single-Dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 540-547.	2.3	27

#	ARTICLE	IF	CITATIONS
152	Drug interactions involving anti-infective agents. , 2010, , 68-103.		2
153	Warfarin-induced skin necrosis in HIV-1-infected patients with tuberculosis and venous thrombosis. South African Medical Journal, 2010, 100, 372.	0.2	7
155	Rifampin Combination Therapy for Nonmycobacterial Infections. Clinical Microbiology Reviews, 2010, 23, 14-34.	5.7	199
156	Effects of Four Different Meal Types on the Population Pharmacokinetics of Single-Dose Rifapentine in Healthy Male Volunteers. Antimicrobial Agents and Chemotherapy, 2010, 54, 3390-3394.	1.4	35
157	Rifampin and Posaconazole Coadministration Leads to Decreased Serum Posaconazole Concentrations. Clinical Infectious Diseases, 2010, 50, 939-940.	2.9	22
158	Itraconazole and Rifampin Alter Significantly the Disposition and Antihistamine Effect of Ebastine and Its Metabolites in Healthy Participants. Journal of Clinical Pharmacology, 2010, 50, 195-204.	1.0	13
159	Methods for the quantitative evaluation and prediction of CYP enzyme induction using human<i>in vitro</i>systems. Expert Opinion on Drug Discovery, 2010, 5, 491-511.	2.5	6
160	Hepatic Drug-Metabolizing Enzyme Induction and Implications for Preclinical and Clinical Risk Assessment. Toxicologic Pathology, 2010, 38, 799-809.	0.9	21
161	Continuous Clindamycin Infusion, an Innovative Approach to Treating Bone and Joint Infections. Antimicrobial Agents and Chemotherapy, 2010, 54, 88-92.	1.4	61
162	Pharmacokinetics of Antituberculosis Drugs in Pulmonary Tuberculosis Patients with Type 2 Diabetes. Antimicrobial Agents and Chemotherapy, 2010, 54, 1068-1074.	1.4	98
163	Rip Van Winkle Wakes Up: Development of Tuberculosis Treatment in the 21st Century. Clinical Infectious Diseases, 2010, 50, S165-S172.	2.9	44
164	Targeted drug delivery of Rifampicin to the lungs: formulation, characterization, and stability studies of preformed aerosolized liposome and in situ formed aerosolized liposome. Drug Development and Industrial Pharmacy, 2010, 36, 638-646.	0.9	22
165	Evaluation of models for predicting drug–drug interactions due to induction. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1399-1416.	1.5	75
166	Pharmacological Issues of Linezolid. Clinical Pharmacokinetics, 2010, 49, 439-447.	1.6	75
167	Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel. Clinical Pharmacokinetics, 2010, 49, 777-798.	1.6	54
168	Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects. Clinical Drug Investigation, 2010, 30, 875-885.	1.1	21
169	Travel-associated Legionnaires disease: clinical features of 17 cases and a review of the literature. Diagnostic Microbiology and Infectious Disease, 2010, 68, 297-303.	0.8	5
171	Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. International Journal of Infectious Diseases, 2010, 14, e1013-e1017.	1.5	20

#	ARTICLE	IF	CITATIONS
172	Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. <i>Pharmacological Reviews</i> , 2011, 63, 157-181.	7.1	546
173	HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 1115-1118.	2.0	3
174	2050: Ending the odyssey of the great white plague. <i>Pharmacological Research</i> , 2011, 64, 176-179.	3.1	5
175	â€˜The tubercular diabeticâ€™™: the impact of diabetes mellitus on tuberculosis and its threat to global tuberculosis control. <i>Clinical Medicine</i> , 2011, 11, 344-347.	0.8	20
176	Challenges and opportunities in developing novel drugs for TB. <i>Future Medicinal Chemistry</i> , 2011, 3, 1373-1400.	1.1	60
178	Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs. <i>Clinical Pharmacokinetics</i> , 2011, 50, 25-39.	1.6	70
179	Chapter 20: Diabetes Mellitus and Tuberculosis Treatment. <i>Progress in Respiratory Research</i> , 2011, , 203-212.	0.1	2
180	The Involvement of Organic Anion Transporting Polypeptide in the Hepatic Uptake of Telmisartan in Rats: PET Studies with [¹¹ C]Telmisartan. <i>Molecular Pharmaceutics</i> , 2011, 8, 1789-1798.	2.3	52
181	Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. <i>Drug and Alcohol Dependence</i> , 2011, 118, 326-334.	1.6	37
182	Nuclear receptor PXR, transcriptional circuits and metabolic relevance. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 956-963.	1.8	177
183	Treatment of latent infection with <i>Mycobacterium tuberculosis</i> : update 2010. <i>European Respiratory Journal</i> , 2011, 37, 690-711.	3.1	104
184	New drugs for tuberculosis treatment. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2011, 29, 47-56.	0.3	6
185	Pregnane X Receptor in Drug Development. , 2011, , .		1
186	Effect of Rifampicin on S-ketamine and S-norketamine Plasma Concentrations in Healthy Volunteers after Intravenous S-ketamine Administration. <i>Anesthesiology</i> , 2011, 114, 1435-1445.	1.3	44
187	Clinical Pharmacology of Anti-Infective Drugs. , 2011, , 1160-1211.		7
188	How close are we to individual analgesic adjustment according to a patientâ€™s genotype?. <i>Personalized Medicine</i> , 2011, 8, 289-292.	0.8	0
189	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidaseâ€™4 inhibitor, in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 92-102.	1.1	27
190	The challenge of new drug discovery for tuberculosis. <i>Nature</i> , 2011, 469, 483-490.	13.7	887

#	ARTICLE	IF	CITATIONS
191	Drug metabolism in the horse: a review. <i>Drug Testing and Analysis</i> , 2011, 3, 19-53.	1.6	48
192	The Clinical Significance of Drug Transporters in Drug Disposition and Drug Interactions. , 2011, , 285-313.		2
194	AtriplaR/anti-TB combination in TB/HIV patients. <i>Drug in focus. BMC Research Notes</i> , 2011, 4, 511.	0.6	4
195	Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. <i>Liver Transplantation</i> , 2011, 17, 1152-1158.	1.3	18
196	Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 175-184.	1.1	33
197	The looming epidemic of diabetes-associated tuberculosis: learning lessons from HIV-associated tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 1436-1445.	0.6	97
198	Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 75-83.	1.0	61
199	Pharmacokinetics of Lopinavir in HIV-Infected Adults Receiving Rifampin with Adjusted Doses of Lopinavir-Ritonavir Tablets. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3195-3200.	1.4	49
200	Contribution of N-Glucuronidation to Efavirenz Elimination <i>in Vivo</i> in the Basal and Rifampin-Induced Metabolism of Efavirenz. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1504-1509.	1.4	32
201	TB and HIV Therapeutics: Pharmacology Research Priorities. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-9.	0.3	19
202	Health-Related Quality of Life (HRQoL) in Co-Morbid Tuberculosis Relapse Patient: A Case Report from Malaysia. <i>Tropical Journal of Pharmaceutical Research</i> , 2012, 11, .	0.2	3
203	Structure-Activity Relationship Modeling for Predicting Interactions with Pregnane X Receptor by Recursive Partitioning. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 506-512.	1.1	5
204	A Semimechanistic Pharmacokinetic-Enzyme Turnover Model for Rifampin Autoinduction in Adult Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2091-2098.	1.4	77
205	Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 446-457.	1.4	154
206	Pharmacokinetics and 48 Week Efficacy of Adjusted Dose Indinavir/Ritonavir in Rifampicin-Treated HIV/Tuberculosis-Coinfected Patients: A Pilot Study. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1170-1176.	0.5	4
207	Investigation of Drug-Drug Interactions Caused by Human Pregnane X Receptor-Mediated Induction of CYP3A4 and CYP2C Subfamilies in Chimeric Mice with a Humanized Liver. <i>Drug Metabolism and Disposition</i> , 2012, 40, 474-480.	1.7	38
208	Telaprevir: Pharmacokinetics and Drug Interactions. <i>Antiviral Therapy</i> , 2012, 17, 1211-1221.	0.6	41
209	Efavirenz, Tenofovir and Emtricitabine Combined with First-Line Tuberculosis Treatment in Tuberculosis-Hiv-Coinfected Tanzanian Patients: A Pharmacokinetic and Safety Study. <i>Antiviral Therapy</i> , 2013, 18, 105-113.	0.6	20

#	ARTICLE	IF	CITATIONS
210	Decrease in the oral bioavailability of dabigatran etexilate after coadministration with rifampicin. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 490-500.	1.1	103
211	Rifampin-zotepine interaction reduces effectiveness of antipsychotic drugs in a stable schizophrenia patient. <i>Psychiatry and Clinical Neurosciences</i> , 2012, 66, 538-538.	1.0	4
212	Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist. <i>AAPS Journal</i> , 2012, 14, 68-78.	2.2	63
213	Rifampicin alters the expression of reference genes used to normalize real-time quantitative RT-PCR data. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 1025-1034.	1.4	8
214	Preclinical study of a potent P-glycoprotein and cytochrome P450 enzyme inducer rifampicin changing pharmacokinetic parameters of risperidone and its metabolite, 9-hydroxyrisperidone, using a rat model. <i>Journal of Pharmaceutical Investigation</i> , 2012, 42, 345-351.	2.7	4
215	New treatment options for multidrug-resistant tuberculosis. <i>Therapeutic Advances in Respiratory Disease</i> , 2012, 6, 255-268.	1.0	34
216	Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 312-322.	4.0	85
217	Effects of CYP Induction by Rifampicin on Tamoxifen Exposure. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 62-67.	2.3	34
218	Global HIV and dermatology. , 2012, , 219-235.		0
219	Hepatotoxicity induced by antituberculosis drugs among patients coinfecting with HIV and tuberculosis. <i>Cadernos De Saude Publica</i> , 2012, 28, 698-708.	0.4	26
220	Genetic and Epigenetic Factors Affecting Cytochrome P450 Phenotype and Their Clinical Relevance. , 2012, , .		3
221	Influence of Rifampicin on the Pharmacokinetics of Salvianolic Acid B May Involve Inhibition of Organic Anion Transporting Polypeptide (Oatp) Mediated Influx. <i>Phytotherapy Research</i> , 2012, 26, 118-121.	2.8	15
222	Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug-Drug Interaction Study in Healthy Male Korean Volunteers. <i>Clinical Therapeutics</i> , 2012, 34, 1182-1194.	1.1	30
223	Rifampicin has a Profound Effect on the Pharmacokinetics of Oral S-ketamine and Less on Intravenous S-ketamine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 111, 325-332.	1.2	42
224	Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 579-587.	1.1	56
225	Model-based approach to dose optimization of lopinavir/ritonavir when administered with rifampicin. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 758-767.	1.1	20
226	Rifampicin markedly decreases the exposure to oral and intravenous tramadol. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1293-1301.	0.8	25
227	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 877-883.	0.8	27

#	ARTICLE	IF	CITATIONS
228	Challenges in the development of drugs for the treatment of tuberculosis. <i>Brazilian Journal of Infectious Diseases</i> , 2013, 17, 74-81.	0.3	36
229	Effect of Chinese herbs on CYP3A4 activity and expression in vitro. <i>Journal of Ethnopharmacology</i> , 2013, 149, 543-549.	2.0	49
230	Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. <i>Pharmacogenomics Journal</i> , 2013, 13, 484-489.	0.9	38
231	3D structures and ligand specificities of nuclear xenobiotic receptors CAR, PXR and VDR. <i>Drug Discovery Today</i> , 2013, 18, 574-581.	3.2	28
232	Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6366-6369.	1.4	112
233	Drug-Induced Liver Injury: The Role of Drug Metabolism and Transport. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 463-474.	1.0	126
234	Describing the Profile of Patients on Concurrent Rifampin and Warfarin Therapy in Western Kenya: A Case Series. <i>Drugs in R and D</i> , 2013, 13, 191-197.	1.1	15
235	Chronological Effects of Rifampicin Discontinuation on Cytochrome P450 Activity in Healthy Japanese Volunteers, Using the Cocktail Method. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 702-708.	2.3	31
236	Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine. <i>International Journal of Drug Policy</i> , 2013, 24, e91-e98.	1.6	34
237	A review of the interplay between tuberculosis and mental health. <i>General Hospital Psychiatry</i> , 2013, 35, 398-406.	1.2	107
238	Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a β_3 -Adrenoceptor Agonist. <i>Clinical Drug Investigation</i> , 2013, 33, 429-440.	1.1	31
239	Pharmacokinetic behavior presents drug therapy challenges. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 627-639.	1.3	0
240	Impact of diabetes mellitus on clinical parameters and treatment outcomes of newly diagnosed pulmonary tuberculosis patients in Thailand. <i>International Journal of Clinical Practice</i> , 2013, 67, 1199-1209.	0.8	35
241	Tests for Latent Tuberculosis in People With ESRD: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2013, 61, 33-43.	2.1	50
242	PXR/CYP3A4-Humanized Mice for Studying Drug-Drug Interactions Involving Intestinal P-Glycoprotein. <i>Molecular Pharmaceutics</i> , 2013, 10, 1056-1062.	2.3	31
243	PXR antagonists and implication in drug metabolism. <i>Drug Metabolism Reviews</i> , 2013, 45, 60-72.	1.5	80
244	The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 431-439.	1.1	35
245	The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 440-449.	1.1	8

#	ARTICLE	IF	CITATIONS
246	Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 507-521.	1.1	19
247	Improving existing tools for <i>Mycobacterium xenopi</i> treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 659-665.	1.3	25
248	Organic anion-transporting polypeptides (OATPs/SLCOs). , 2013, , 353-454.		0
249	Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin. <i>Drug Metabolism and Disposition</i> , 2013, 41, 966-974.	1.7	55
250	Phenytoinâ€Rifampin Drug Interaction in a Hypoalbuminemic, Renal Failure Patient: A Complex Clinical Case. <i>Pharmacotherapy</i> , 2013, 33, e96-100.	1.2	5
251	Modelâ€based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 741-751.	1.1	12
252	Regulation of MicroRNA Expression by Rifampin in Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1763-1768.	1.7	33
253	Hepatic Cyp2d and Cyp26a1 mRNAs and Activities Are Increased During Mouse Pregnancy. <i>Drug Metabolism and Disposition</i> , 2013, 41, 312-319.	1.7	16
254	Diabetes mellitus and tuberculosis facts and controversies. <i>Journal of Diabetes and Metabolic Disorders</i> , 2013, 12, 58.	0.8	90
255	Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naïve patients with HIV and tuberculosis infections in India: a pilot study. <i>BMC Infectious Diseases</i> , 2013, 13, 482.	1.3	17
256	Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1106-1114.	1.3	98
257	Three new shRNA expression vectors targeting the CYP3A4 coding sequence to inhibit its expression. <i>Acta Pharmaceutica Sinica B</i> , 2014, 4, 350-357.	5.7	2
258	Factors Associated with Variability in Rifampin Plasma Pharmacokinetics and the Relationship between Rifampin Concentrations and Induction of Efavirenz Clearance. <i>Pharmacotherapy</i> , 2014, 34, 265-271.	1.2	24
259	The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 51-56.	0.8	6
260	Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1113-1124.	1.1	13
261	The impact of coâ€administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1050-1057.	1.1	25
262	Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-X_L , in patients with cancer. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 680-684.	0.7	9
263	Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 56, 1-15.	1.9	65

#	ARTICLE	IF	CITATIONS
264	Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir. <i>Clinical Drug Investigation</i> , 2014, 34, 173-182.	1.1	52
266	Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combination. <i>European Journal of Dermatology</i> , 2014, 24, 94-95.	0.3	37
267	Structural Basis for Inhibition of Mycobacterial and Human Adenosine Kinase by 7-Substituted 7-(Het)aryl-7-deazaadenine Ribonucleosides. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8268-8279.	2.9	26
268	Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1079-1085.	1.3	54
269	Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults. <i>Clinical Drug Investigation</i> , 2014, 34, 651-659.	1.1	61
270	Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 675-684.	0.8	3
271	Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide. <i>AAPS Journal</i> , 2014, 16, 736-748.	2.2	47
272	Concomitant Use of Carbamazepine and Rifampin in a Patient With <i>Mycobacterium avium</i> Complex and Seizure Disorder. <i>Journal of Pharmacy Technology</i> , 2014, 30, 93-96.	0.5	4
273	Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide clinical probe than rosuvastatin. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 587-598.	1.1	138
274	Treatment Optimization in Patients Co-Infected with HIV and <i>Mycobacterium tuberculosis</i> Infections: Focus on Drug-Drug Interactions with Rifamycins. <i>Clinical Pharmacokinetics</i> , 2014, 53, 489-507.	1.6	62
275	Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 609-620.	1.5	3
276	Drug interaction between bortezomib and tuberculosis treatment: a case report. <i>European Journal of Hospital Pharmacy</i> , 2014, 21, 167-169.	0.5	1
277	Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1012-1023.	1.0	67
278	The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 25-32.	0.8	3
279	Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 63-73.	0.8	25
280	Nuclear Receptors in Drug Metabolism, Drug Response and Drug Interactions. <i>Nuclear Receptor Research</i> , 2015, 2, .	2.5	90
281	Factors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South Africa. <i>PLoS ONE</i> , 2015, 10, e0133452.	1.1	24
282	Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. <i>PLoS ONE</i> , 2015, 10, e0141002.	1.1	73

#	ARTICLE	IF	CITATIONS
283	Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions. <i>Pharmaceutical Research</i> , 2015, 32, 2477-502.	1.7	14
284	Parsing interindividual drug variability: an emerging role for systems pharmacology. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2015, 7, 221-241.	6.6	57
285	Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1558-1566.	1.3	77
286	Characterization of Mouse Models of Mycobacterium avium Complex Infection and Evaluation of Drug Combinations. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2129-2135.	1.4	40
287	Species differences and substrate specificity of CYP3A heteroactivation by efavirenz. <i>Xenobiotica</i> , 2015, 45, 345-352.	0.5	8
288	Embolismo pulmonar masivo en un paciente con tuberculosis pulmonar: una entidad más que una asociación. <i>Acta Colombiana De Cuidado Intensivo</i> , 2015, 15, 143-146.	0.1	1
289	Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 57-63.	0.3	24
290	Exposure to Total and Protein-Unbound Rifampin Is Not Affected by Malnutrition in Indonesian Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3233-3239.	1.4	22
291	Nano-formulation of rifampicin with enhanced bioavailability: Development, characterization and in-vivo safety. <i>International Journal of Pharmaceutics</i> , 2015, 485, 138-151.	2.6	45
292	Pharmacological Interactions Between Rifampicin and Antiretroviral Drugs. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 22-32.	1.0	42
293	Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. <i>Infection</i> , 2015, 43, 473-481.	2.3	31
294	Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children. <i>Clinical Infectious Diseases</i> , 2015, 61, S188-S199.	2.9	8
295	The anti-tuberculosis agents under development and the challenges ahead. <i>Future Medicinal Chemistry</i> , 2015, 7, 1981-2003.	1.1	28
296	Effects of multiple-dose rifampicin 450mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 98-103.	0.7	8
297	Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, S42-S46.	0.6	24
298	Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7707-7714.	1.4	24
299	Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1795-1804.	1.7	37
300	Tackling virological failure in HIV-infected children living in Africa. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1213-1223.	2.0	14

#	ARTICLE	IF	CITATIONS
301	Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90 ^α as a Novel Mechanism of Rifampin-induced MDR1 Expression. <i>Journal of Biological Chemistry</i> , 2015, 290, 17029-17040.	1.6	26
302	New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 273-293.	1.5	52
303	Prescribing clozapine and rifampicin: clinical impact of their interaction. <i>BJPsych Bulletin</i> , 2016, 40, 153-155.	0.7	7
304	Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. <i>Frontiers in Pharmacology</i> , 2016, 7, 111.	1.6	32
305	Rifamycins. , 2016, , 132-170.		2
306	Characterization of equine cytochrome P450: role of CYP3A in the metabolism of diazepam. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2016, 39, 478-487.	0.6	7
307	Treatment of prosthetic joint infections due to <i>Propionibacterium</i> . <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2016, 87, 60-66.	1.2	38
308	Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00271.	1.1	9
309	Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 377-378.	0.8	5
310	Establishment of In Silico Prediction Models for CYP3A4 and CYP2B6 Induction in Human Hepatocytes by Multiple Regression Analysis Using Azole Compounds. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1390-1398.	1.7	12
311	Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis. <i>Drug Metabolism and Disposition</i> , 2016, 44, 792-799.	1.7	36
312	Insights into the pharmacokinetic properties of antitubercular drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 765-778.	1.5	3
313	New agents for the treatment of drug-resistant <i>Mycobacterium tuberculosis</i> . <i>Advanced Drug Delivery Reviews</i> , 2016, 102, 55-72.	6.6	269
314	Pharmacokinetic drug interactions of the selective androgen receptor modulator CTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. <i>Investigational New Drugs</i> , 2016, 34, 458-467.	1.2	18
315	CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. <i>Pharmacogenomics</i> , 2016, 17, 603-613.	0.6	15
316	Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2016, 51, S61-S70.	1.0	54
317	Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5976-5985.	1.4	56
318	<i>Mycobacterium Tuberculosis</i> (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 160-185.	2.6	52

#	ARTICLE	IF	CITATIONS
319	Effect of antituberculosis treatment on <sc>CYP</sc>2C19 enzyme activity in genetically polymorphic South Indian Tamilian population. <i>Fundamental and Clinical Pharmacology</i> , 2016, 30, 607-615.	1.0	0
320	Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 63, e147-e195.	2.9	916
322	Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 905-916.	0.8	58
323	Population Pharmacokinetics of Rifampicin in Chinese Patients With Pulmonary Tuberculosis. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 622-627.	1.0	12
324	Acetylation of lysine 109 modulates pregnane X receptor DNA binding and transcriptional activity. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 1155-1169.	0.9	18
325	Pairwise antibiotic interactions in <i>Escherichia coli</i> : triclosan, rifampicin and aztreonam with nine other classes of antibiotics. <i>Journal of Antibiotics</i> , 2016, 69, 791-797.	1.0	12
326	Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 119-127.	1.0	87
327	Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. <i>Drug Metabolism and Pharmacokinetics</i> , 2016, 31, 107-116.	1.1	14
328	Trial watch “inhibiting PARP enzymes for anticancer therapy. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1053594.	0.3	19
329	Rifampin “sirolimus” voriconazole interaction in a hematopoietic cell transplant recipient. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 75-79.	0.5	10
330	Coadministration of Rifampin Significantly Reduces Odanacatib Concentrations in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 110-117.	1.0	2
331	Pyridines: Multidrug-resistant tuberculosis (MDR-TB) inhibitors. <i>Indian Journal of Tuberculosis</i> , 2017, 64, 119-128.	0.3	19
332	Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 175-184.	0.8	21
333	Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome. <i>Drug Metabolism and Disposition</i> , 2017, 45, 501-511.	1.7	14
334	The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 135-146.	0.7	25
335	Rifampicin reverses nicardipine effect inducing uncontrolled essential hypertension. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 587-589.	1.0	8
336	Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2242-2248.	1.1	49
337	Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 106, 20-33.	1.9	18

#	ARTICLE	IF	CITATIONS
338	Alterations of Histone Modifications Contribute to Pregnane X Receptor-Mediated Induction of CYP3A4 by Rifampicin. <i>Molecular Pharmacology</i> , 2017, 92, 113-123.	1.0	26
339	The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2017, 37, 659-667.	1.1	41
340	Differential activation of pregnane X receptor by carnosic acid, carnosol, ursolic acid, and rosmarinic acid. <i>Pharmacological Research</i> , 2017, 120, 23-33.	3.1	22
341	Management of hidradenitis suppurativa in pregnancy. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 979-989.	0.6	30
342	Correlations between the enantio- and regio-selective metabolisms of warfarin. <i>Pharmacogenomics</i> , 2017, 18, 133-142.	0.6	0
343	Suppression of miR-628-3p and miR-641 is involved in rifampin-mediated CYP3A4 induction in HepaRG cells. <i>Pharmacogenomics</i> , 2017, 18, 57-64.	0.6	19
344	Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	57
345	RSSDI clinical practice recommendations for diagnosis, prevention, and control of the diabetes mellitus-tuberculosis double burden. <i>International Journal of Diabetes in Developing Countries</i> , 2017, 37, 379-399.	0.3	1
346	Impact of enzalutamide and its main metabolite <i>N</i> -desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters. <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 517-525.	1.1	18
347	Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2778-2788.	1.1	13
348	Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	17
350	Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 280-291.	0.8	38
351	The challenges of pharmacokinetic variability of first-line anti-TB drugs. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 47-58.	1.3	23
352	Production of Superoxide in Bacteria Is Stress- and Cell State-Dependent: A Gating-Optimized Flow Cytometry Method that Minimizes ROS Measurement Artifacts with Fluorescent Dyes. <i>Frontiers in Microbiology</i> , 2017, 8, 459.	1.5	79
353	Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naïve patients with HIV and Tuberculosis infections in India: a multi-centre study. <i>BMC Infectious Diseases</i> , 2017, 17, 761.	1.3	12
354	Neuropsychiatric Complexities in the HIV Patient – Clinical Challenges beyond Neurocognitive Disorders. <i>Journal of AIDS & Clinical Research</i> , 2017, 08, .	0.5	0
356	Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1559-1570.	1.6	69
357	Rifampin modulation of xenobiotic and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00386.	1.1	18

#	ARTICLE	IF	CITATIONS
358	Drugs for Tuberculosis. , 2018, , 221-253.		5
359	Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 186-196.	1.3	41
360	Tuberculosis Recommendations for Solid Organ Transplant Recipients and Donors. Transplantation, 2018, 102, S60-S65.	0.5	21
361	Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 59-82.	1.5	36
362	Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole. Journal of Clinical Pharmacology, 2018, 58, 347-356.	1.0	19
363	Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects. Journal of Clinical Pharmacology, 2018, 58, 193-201.	1.0	13
364	Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. Journal of Thoracic Disease, 2018, 10, 3102-3118.	0.6	34
365	Comparison of the Drug-Drug Interaction Potential of Daptomycin in Combination with Rifampin in Healthy Adult Volunteers. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	3
367	Characterization of CYP2C Induction in Cryopreserved Human Hepatocytes and Its Application in the Prediction of the Clinical Consequences of the Induction. Journal of Pharmaceutical Sciences, 2018, 107, 2479-2488.	1.6	11
368	Pharmacokinetic Differences Between Cobicistat and Ritonavir on Warfarin. Annals of Pharmacotherapy, 2018, 52, 1165-1166.	0.9	2
369	Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatment. International Journal of Pharmaceutics, 2018, 548, 244-254.	2.6	17
370	The development and validation of a LC-MS/MS method for the quantitation of metformin, rifampicin and isoniazid in rat plasma using HILIC chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1095, 127-137.	1.2	11
371	Using quantitative systems pharmacology to evaluate the drug efficacy of COX-2 and 5-LOX inhibitors in therapeutic situations. Npj Systems Biology and Applications, 2018, 4, 28.	1.4	15
372	Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	37
373	Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. European Journal of Clinical Pharmacology, 2018, 74, 1593-1604.	0.8	11
374	Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors. Journal of Clinical Pharmacology, 2018, 58, 1629-1638.	1.0	13
375	Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 845-857.	1.3	28
376	Adjuvant immunosuppression for paradoxical deterioration in tuberculous meningitis including one case responsive to cyclosporine. A tertiary referral hospital experience. Journal of the Neurological Sciences, 2019, 404, 58-62.	0.3	4

#	ARTICLE	IF	CITATIONS
377	Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	2
378	Effect of rifampicin and clarithromycin on the CYP3A activity in patients with <i>Mycobacterium avium</i> complex. <i>Journal of Thoracic Disease</i> , 2019, 11, 3814-3821.	0.6	8
379	Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 371-374.	1.1	6
380	Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1620-1631.	1.0	5
381	Tests for latent tuberculosis in candidates for solid organ transplantation: A systematic review and meta-analysis. <i>Clinical Transplantation</i> , 2019, 33, e13643.	0.8	7
382	The optimization of methadone dosing whilst treating with rifampicin: A pharmacokinetic modeling study. <i>Drug and Alcohol Dependence</i> , 2019, 200, 168-180.	1.6	14
383	Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	19
384	Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 202-206.	1.1	31
385	Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1670-1678.	1.3	42
386	Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1345-1361.	2.3	107
387	Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. <i>Journal of Pharmacological Sciences</i> , 2019, 139, 361-366.	1.1	12
388	A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys. <i>Biopharmaceutics and Drug Disposition</i> , 2019, 40, 81-93.	1.1	7
389	In Vitro Evaluation of the Drug Interaction Potential of Doravirine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	22
390	Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2019, 39, 441-451.	1.1	12
391	Successful establishment of third-line antiretroviral therapy in Malawi: lessons learned. <i>Public Health Action</i> , 2019, 9, 169-173.	0.4	2
392	Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 730-737.	2.3	16
393	A practical approach to tuberculosis diagnosis and treatment in liver transplant recipients in a low-prevalence area. <i>Médecine Et Maladies Infectieuses</i> , 2019, 49, 231-240.	5.1	9
394	Population Pharmacokinetic Modelling of Pyrazinamide and Pyrazinoic Acid in Patients with Multi-Drug Resistant Tuberculosis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 519-530.	0.6	9

#	ARTICLE	IF	CITATIONS
395	Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 195-205.	0.8	21
396	Voriconazole Autoinduction and Saturable Metabolism After Cessation of Rifampin in a Patient With Invasive Central Nervous System <i>Aspergillus</i> : Importance of Therapeutic Drug Monitoring. <i>Journal of Pharmacy Practice</i> , 2019, 32, 589-594.	0.5	8
397	Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. <i>Artificial Organs</i> , 2020, 44, 140-152.	1.0	84
398	Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 86-95.	1.0	13
399	Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2020, 59, 617-627.	1.6	17
400	Therapeutic drug monitoring of antimicrobial, antifungal and antiviral agents. , 2020, , 159-197.		3
401	Computational prediction of cytochrome P450 inhibition and induction. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, 30-44.	1.1	40
402	Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
403	Safety implications of combined antiretroviral and anti-tuberculosis drugs. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 23-41.	1.0	24
404	Influence of Renal Function and Age on the Pharmacokinetics of Levofloxacin in Patients with Bone and Joint Infections. <i>Antibiotics</i> , 2020, 9, 401.	1.5	6
405	Rifampicin Transport by OATP1B1 Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	4
406	Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition. <i>Pharmaceutical Research</i> , 2020, 37, 208.	1.7	15
407	Attainment of therapeutic posaconazole serum levels during co-administration with rifampicin. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 284-285.	0.9	2
408	Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 139-151.	1.3	7
409	The Necessity of Using Changes in Absorption Time to Implicate Intestinal Transporter Involvement in Oral Drug-Drug Interactions. <i>AAPS Journal</i> , 2020, 22, 111.	2.2	10
410	Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents. <i>Pharmaceuticals</i> , 2020, 13, 439.	1.7	21
411	Comparative analysis of the drug-drug interaction between immunosuppressants, safety and efficacy of rifabutin from rifampicin-based Anti-TB treatment in living donor liver transplant recipients with active tuberculosis. <i>Biomedical Journal</i> , 2020, , .	1.4	4
412	The pharmacology of antibiotic therapy in hidradenitis suppurativa. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 521-530.	1.3	13

#	ARTICLE	IF	CITATIONS
413	Repeated dose multi-drug testing using a microfluidic chip-based coculture of human liver and kidney proximal tubules equivalents. <i>Scientific Reports</i> , 2020, 10, 8879.	1.6	23
414	An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1519-1526.	1.0	7
415	Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel. <i>Clinical and Translational Science</i> , 2020, 13, 886-890.	1.5	9
416	Pharmacokinetics, Safety/tolerability, and Efficacy of high-dose Rifampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). <i>Trials</i> , 2020, 21, 181.	0.7	14
417	Susceptibility of invasive <i>Neisseria meningitidis</i> strains isolated in Germany to azithromycin, an alternative agent for post-exposure prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 984-987.	1.3	6
418	Inhalable dry powders of rifampicin highlighting potential and drawbacks in formulation development for experimental tuberculosis aerosol therapy. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 305-322.	2.4	5
419	Pregnane X Receptor Activator Rifampin Increases Blood Pressure and Stimulates Plasma Renin Activity. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 856-865.	2.3	16
420	Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1149-1160.	1.6	16
421	Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1135-1148.	1.6	27
422	Mycobacterial Cell Wall: A Source of Successful Targets for Old and New Drugs. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2278.	1.3	44
423	Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 299-306.	0.8	4
424	Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1334-1341.	2.3	7
425	Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 471-484.	2.3	10
426	Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2021, 60, 205-222.	1.6	11
427	Is Rifampin Use Associated With Better Outcome in Staphylococcal Prosthetic Valve Endocarditis? A Multicenter Retrospective Study. <i>Clinical Infectious Diseases</i> , 2021, 72, e249-e255.	2.9	9
428	Drug exposure of first-line anti-tuberculosis drugs in China: A prospective pharmacological cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1347-1358.	1.1	13
429	Improved Prediction of the Drug-Drug Interactions of Pemaflibrate Caused by Cyclosporine A and Rifampicin via PBPK Modeling: Consideration of the Albumin-Mediated Hepatic Uptake of Pemaflibrate and Inhibition Constants With Preincubation Against OATP1B. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 517-528.	1.6	6
430	Effects of rifampicin on plasma pharmacokinetics of tulathromycin in goats. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2021, 44, 374-380.	0.6	0

#	ARTICLE	IF	CITATIONS
431	Genetic Polymorphism Effect on Warfarinâ€“Rifampin Interaction: A Case Report and Review of Literature. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 149-156.	0.4	3
432	Cellular and Molecular Mechanisms of Repurposed Antidiabetic Drug as an Adjunctive Treatment for Tuberculosis. , 2021, , 355-372.		1
433	Effect of rifampicin on anticoagulation of warfarin: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 1087-1095.	0.3	2
434	Hostâ€“directed therapy to combat mycobacterial infections*. <i>Immunological Reviews</i> , 2021, 301, 62-83.	2.8	71
435	Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. <i>Clinical Pharmacokinetics</i> , 2021, 60, 685-710.	1.6	39
436	The pharmacokinetics and drug-drug interactions of ivermectin in <i>Aedes aegypti</i> mosquitoes. <i>PLoS Pathogens</i> , 2021, 17, e1009382.	2.1	3
437	Hepatic transporterâ€“mediated pharmacokinetic drugâ€“drug interactions: Recent studies and regulatory recommendations. <i>Biopharmaceutics and Drug Disposition</i> , 2021, 42, 45-77.	1.1	3
438	Pharmacokinetic Drug-drug Interaction of Antibiotics Used in Sepsis Care in China. <i>Current Drug Metabolism</i> , 2021, 22, 5-23.	0.7	4
439	Potential metabolic resistance mechanisms to ivermectin in <i>Anopheles gambiae</i> : a synergist bioassay study. <i>Parasites and Vectors</i> , 2021, 14, 172.	1.0	12
441	Effects of Xiaochaihu decoction on the expression of cytochrome P450s in rats. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 588.	0.8	4
442	GLPG1205, a GPR84 Modulator: Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 994-1006.	0.8	5
443	The NIMS framework: an approach to the evaluation and management of epidural abscesses. <i>Spine Journal</i> , 2021, 21, 1965-1972.	0.6	6
444	Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 162, 1-11.	2.0	11
445	Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010â€“2020 Review. <i>Pharmaceutics</i> , 2021, 14, 461.	1.7	31
446	Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 369-377.	1.1	5
447	An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 42, 100410.	1.1	19
448	Tuberculosis in Solid Organ Transplantation: Insights from TB Endemic Areas. <i>Current Infectious Disease Reports</i> , 2021, 23, 1.	1.3	2
449	Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury. <i>Cells</i> , 2021, 10, 1846.	1.8	18

#	ARTICLE	IF	CITATIONS
450	CYP3A4—22 Genotyping in Clinical Practice: Ready for Implementation?. <i>Frontiers in Genetics</i> , 2021, 12, 711943.	1.1	32
451	Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0104321.	1.4	13
452	Pharmacokinetic and Safety Profile of the Novel HIV Nucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0093521.	1.4	1
453	Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 385-396.	1.0	4
454	Enzyme Induction and Drug Metabolism. , 2021, , 1-7.		0
455	The Impact and In Vitro to In Vivo Prediction of Transporter-Based Drug-Drug Interactions in Humans. , 2010, , 517-553.		4
456	Drugs for Tuberculosis. , 2011, , 401-424.		2
457	Role of CYP2B6 in Stereoselective Human Methadone Metabolism. <i>Anesthesiology</i> , 2008, 108, 363-374.	1.3	174
458	Rifampin Greatly Reduces the Plasma Concentrations of Intravenous and Oral Oxycodone. <i>Anesthesiology</i> , 2009, 110, 1371-1378.	1.3	90
459	Mutual repression between steroid and xenobiotic receptor and NF- κ B signaling pathways links xenobiotic metabolism and inflammation. <i>Journal of Clinical Investigation</i> , 2006, 116, 2280-2289.	3.9	335
460	Cytochrome P450-mediated metabolism in the human gut wall. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 541-558.	1.2	130
461	Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis. <i>American Journal of Case Reports</i> , 2017, 18, 1130-1134.	0.3	5
462	Clinical Outcomes of Tuberculosis in Recipients After Living Donor Liver Transplantation. <i>Annals of Transplantation</i> , 2018, 23, 733-743.	0.5	12
463	The role of cytochrome P450 in antiretroviral drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 583-598.	1.5	42
464	Drogas antituberculose: interações medicamentosas, efeitos adversos e utilização em situações especiais - parte 1: fármacos de primeira linha. <i>Jornal Brasileiro De Pneumologia</i> , 2010, 36, 626-640.	0.4	154
465	Tuberculosis - Present Medication and Therapeutic Prospects. <i>Current Medicinal Chemistry</i> , 2020, 27, 630-656.	1.2	2
466	The Transcriptional Regulation of the Human CYP2C Genes. <i>Current Drug Metabolism</i> , 2009, 10, 567-578.	0.7	112
467	The Role of Drug Transporters in the Pharmacokinetics of Antibiotics. <i>Current Drug Metabolism</i> , 2016, 17, 799-805.	0.7	8

#	ARTICLE	IF	CITATIONS
468	Influence of Rifampicin Pre-treatment on the In vivo Pharmacokinetics of Metoclopramide in Pakistani Healthy Volunteers Following Concurrent Oral Administration. <i>Current Drug Metabolism</i> , 2020, 21, 301-306.	0.7	2
469	Advances in Drug Discovery and Development for Pediatric Tuberculosis. <i>Mini-Reviews in Medicinal Chemistry</i> , 2016, 16, 481-497.	1.1	11
470	Effect of Acute and Repeated Administration of Methamphetamine on the Activity of CYP2D in Isolated Perfused Rat Liver. <i>Acta Veterinaria Brno</i> , 2005, 74, 339-345.	0.2	1
471	Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact. <i>Indian Journal of Nephrology</i> , 2016, 26, 322.	0.2	16
472	Topics on Drug Metabolism. , 2012, , .		9
473	Burden of comorbidities and their treatment in patients with active tuberculosis: A prospective study. <i>The Journal of Clinical and Scientific Research</i> , 2021, 10, 202.	0.1	0
474	Rifampicin & food effect. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2004, 35, 89S-89S.	0.1	0
475	Molecular Mechanisms of Endocrine Disruption in Estrogen Dependent Processes. , 2004, , 217-247.		0
476	Drug-Drug Interaction & Enzyme Induction. , 2006, , 543-550.		0
477	Decreased Serum Aprindine Levels During Anti-Tuberculous Therapy in Two Cases of End-stage Renal Disease. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2008, 34, 871-875.	0.0	0
478	Drug Disposition and Drug-Drug Interactions: Importance of First-Pass Metabolism in Gut and Liver. , 2010, , 415-435.		1
480	Lack of Pharmacokinetic Interaction between Pilsicainide and Rifampicin in Healthy Volunteers. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 44, 301-305.	0.1	0
481	Application of Clearance Theory to the Evaluation and Provision of Drug Information on Renal Dysfunction and Drug-drug Interactions. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health)</i> Tj ETQq0 0 0 rgB0 /Overlock 10 Tf 5		0
482	Drug Discovery for TB: Frontiers and Perspectives. , 2014, , 3-31.		1
483	Immunologic and Virologic Responses to Nevirapine Based Antiretroviral Therapy (ART) Among HIV-tuberculosis Co-infected Ugandan Children on Rifampicin Based Anti-tubercular Treatment. <i>HIV/AIDS Research and Treatment: Open Journal</i> , 2015, 2, 27-36.	0.2	0
484	Highly Active Antiretroviral Therapy and Anti-tuberculosis Drug Interactions with Associated Clinical Implications: A Review. <i>Journal of Drug Metabolism & Toxicology</i> , 2016, 7, .	0.1	0
485	Drug Interactions in Anesthesia. , 2017, , 313-325.		0
486	Pharmacology of Drug Resistance. , 2017, , 37-43.		0

#	ARTICLE	IF	CITATIONS
487	STUDY ON CLINICAL AND RADIOLOGICAL PRESENTATION OF PULMONARY TUBERCULOSIS IN DIABETIC PATIENTS IN A TERTIARY CARE HOSPITAL. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2017, 4, 4622-4626.	0.0	1
488	A QUESTIONNAIRE STUDY ON THE EVALUATION OF DIFFERENT PHARMACOKINETIC DRUG INTERACTIONS IN THE INTENSIVE CARE UNIT OF AL-THOURA TEACHING HOSPITAL IN EL-BEIDA, LIBYA. , 2019, 4, 20-23.		0
489	Reasons for Antiretroviral Treatment Change Among Adult HIV/AIDS Patients at Nedjo General Hospital, Western Ethiopia. <i>Open AIDS Journal</i> , 2019, 13, 65-73.	0.1	2
491	Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs. <i>Acta Medica Martiniana</i> , 2020, 20, 45-55.	0.4	0
492	Variation in Expression of Cytochrome P450 3A Isoforms and Toxicological Effects: Endo- and Exogenous Substances as Regulatory Factors and Substrates. <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 1617-1634.	0.6	16
494	Analyzing Potential Intestinal Transporter Drug-Drug Interactions: Reevaluating Ticagrelor Interaction Studies. <i>Pharmaceutical Research</i> , 2021, 38, 1639-1644.	1.7	3
496	Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers. <i>Anesthesia and Analgesia</i> , 2021, 133, 423-434.	1.1	1
498	Drug interactions: a primer for the gastroenterologist. <i>Gastroenterology and Hepatology</i> , 2012, 8, 376-83.	0.2	4
500	Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin. <i>Indian Journal of Medical Research</i> , 2012, 136, 979-84.	0.4	8
501	Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium. <i>Indian Journal of Medical Research</i> , 2013, 137, 455-93.	0.4	20
502	Cytochrome P450 enzyme mediated herbal drug interactions (Part 2). <i>EXCLI Journal</i> , 2014, 13, 869-96.	0.5	31
504	Anti-diabetics and antimicrobials: Harmony of mutual interplay. <i>World Journal of Diabetes</i> , 2021, 12, 1832-1855.	1.3	31
505	Clinical Relevance of Rifampicin-Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0182921.	1.4	4
506	Adverse Drug Reactions Related to Treatment of Drug-Susceptible Tuberculosis in Brazil: A Prospective Cohort Study. <i>Frontiers in Tropical Diseases</i> , 2022, 2, .	0.5	11
507	The impact of diabetes mellitus on the pharmacokinetics of rifampicin among tuberculosis patients: A systematic review and meta-analysis study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102410.	1.8	2
509	Study on the associations between liver damage and antituberculosis drug rifampicin and relative metabolic enzyme gene polymorphisms. <i>Bioengineered</i> , 2021, 12, 11700-11708.	1.4	8
510	Cytochrome P450 and P-gp mediated herb-drug interactions of some common Indian herbs. <i>Studies in Natural Products Chemistry</i> , 2022, , 225-258.	0.8	1
511	Intensified Antituberculosis Therapy Regimen Containing Higher Dose Rifampin for Tuberculous Meningitis: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 822201.	1.2	2

#	ARTICLE	IF	CITATIONS
512	Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 975-987.	0.8	3
513	Chapter 10: Treatment of active tuberculosis in special populations. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2022, 6, 149-166.	0.2	1
514	Treatment Strategies and Challenges in the Co-Management of Type 2 Diabetes and Tuberculosis. <i>Journal of Pharmacy and Nutrition Sciences (discontinued)</i> , 0, 12, 1-10.	0.2	0
515	Urinary excretion of metformin in diabetic patients with and without tuberculosis. <i>Indian Journal of Tuberculosis</i> , 2022, , .	0.3	0
516	Elevated Levels of Three Reactive Oxygen Species and Fe(II) in the Antibiotic-Surviving Population of Mycobacteria Facilitate <i>De Novo</i> Emergence of Genetic Resisters to Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0228521.	1.4	12
519	A literature review of liver function test elevations in rifampin <i>drug-drug</i> interaction studies. <i>Clinical and Translational Science</i> , 2022, 15, 1561-1580.	1.5	6
520	A Case Series of Rifabutin Use in Staphylococcal Prosthetic Infections. <i>Microbiology Spectrum</i> , 2022, 10, e0038422.	1.2	3
521	Pharmacokinetics and 48-Week Efficacy of Nevirapine: 400 mg Versus 600 mg per day in HIV-Tuberculosis Coinfection Receiving Rifampicin. <i>Antiviral Therapy</i> , 2008, 13, 529-536.	0.6	36
522	Robust physiologically based pharmacokinetic model of rifampicin for predicting <i>drug-drug</i> interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 919-933.	1.3	11
523	Impact of diabetes mellitus on rifampicin's plasma concentration and bioavailability in patients with tuberculosis: A systematic review and meta-analysis study. <i>Therapie</i> , 2023, 78, 313-324.	0.6	2
524	Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 6-27.	1.9	17
525	Erratic enteric absorption of dolutegravir in a critically ill patient. <i>Revista Espanola De Quimioterapia</i> , 0, , .	0.5	0
526	Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice. <i>Antibiotics</i> , 2022, 11, 701.	1.5	9
527	Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210958.	1.1	6
528	Enzyme Induction and Drug Metabolism. , 2022, , 471-478.		0
529	Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles. <i>International Journal of Pharmaceutics</i> , 2022, 622, 121893.	2.6	5
530	Pharmacometrics in tuberculosis: progress and opportunities. <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106620.	1.1	3
531	Alternatives to rifampicin: A review and perspectives on the choice of strong <i>CYP3A</i> inducers for clinical <i>drug-drug</i> interaction studies. <i>Clinical and Translational Science</i> , 2022, 15, 2075-2095.	1.5	7

#	ARTICLE	IF	CITATIONS
532	Infective Endocarditis in the Elderly: Challenges and Strategies. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 192.	0.8	7
533	Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	3
534	High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
536	Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin. <i>Clinical Infectious Diseases</i> , 2023, 76, e910-e919.	2.9	9
537	Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. <i>Lancet HIV</i> , 2022, 9, e627-e637.	2.1	10
538	Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?. <i>Children</i> , 2022, 9, 1120.	0.6	9
539	Receptors and drug-metabolizing enzymes: From function to regulation. , 2022, , 161-190.		0
540	Pharmacology and early ADMET data of coralopyronin A, a natural product with macrofilaricidal anti-wolbachial activity in filarial nematodes. <i>Frontiers in Tropical Diseases</i> , 0, 3, .	0.5	3
541	Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	1.4	0
542	The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 409-415.	1.1	3
543	Possible agent for COVID-19 treatment: Rifampicin. <i>World Journal of Virology</i> , 0, 11, 391-393.	1.3	0
544	Drug interaction between anti-tubercular medication and clozapine leading to relapse of psychosis: A case report. <i>Asian Journal of Psychiatry</i> , 2022, 77, 103279.	0.9	1
545	M. tuberculosis Transcription Machinery: A Review on the Mycobacterial RNA Polymerase and Drug Discovery Efforts. <i>Life</i> , 2022, 12, 1774.	1.1	4
547	Analysis of Time-Dependent Pharmacokinetics Using In Vitroâ€œIn Vivo Extrapolation and Physiologically Based Pharmacokinetic Modeling. <i>Pharmaceutics</i> , 2022, 14, 2562.	2.0	0
548	Current Medical and Surgical Treatment of Hidradenitis Suppurativaâ€œA Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 7240.	1.0	14
549	New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians. <i>Respiration</i> , 2023, 102, 83-100.	1.2	9
550	Characterizing complex and competing drugâ€œdrug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine. <i>Clinical and Translational Science</i> , 2023, 16, 593-605.	1.5	4
551	What Is Known about Midazolam? A Bibliometric Approach of the Literature. <i>Healthcare (Switzerland)</i> , 2023, 11, 96.	1.0	3

#	ARTICLE	IF	CITATIONS
552	Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis. <i>Antibiotics</i> , 2023, 12, 702.	1.5	1
553	Shikimate Kinase Inhibitors: An Update on Promising Strategy against <i>Mycobacterium tuberculosis</i> . <i>Current Drug Targets</i> , 2023, 24, 388-405.	1.0	1
555	Physiologically Based Pharmacokinetic Modeling Characterizes the Drug-Drug Interaction Between Saxagliptin and Rifampicin in Patients With Renal Impairment. <i>Journal of Clinical Pharmacology</i> , 2023, 63, 848-858.	1.0	2
556	Dried Blood Spot Sampling to Assess Rifampicin Exposure and Treatment Outcomes among Native and Non-Native Tuberculosis Patients in Paraguay: An Exploratory Study. <i>Pharmaceutics</i> , 2023, 15, 1089.	2.0	0
557	Comparing the Synergistic and Antagonistic Interactions of Ciprofloxacin and Levofloxacin Combined with Rifampin against Drug-Resistant <i>Staphylococcus aureus</i> : A Time-Kill Assay. <i>Antibiotics</i> , 2023, 12, 711.	1.5	0
558	Impact of clinical pharmacist interventions in a Bone and joint infection orthoseptic surgery unit. <i>Annales Pharmaceutiques Francaises</i> , 2023, , .	0.4	0